News
US FDA clears Instil Bio’s IND application for AXN-2510, a PD-L1xVEGF bispecific antibody, for a phase 1 trial in relapsed/refractory solid tumours: Dallas Friday, July 4, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback